Your browser doesn't support javascript.
loading
Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.
Nakaigawa, Noboru; Tomita, Yoshihiko; Tamada, Satoshi; Tatsugami, Katsunori; Osawa, Takahiro; Oya, Mototsugu; Kanayama, Hiroomi; Miura, Yuji; Sassa, Naoto; Nishimura, Kazuo; Nozawa, Masahiro; Masumori, Naoya; Miyoshi, Yasuhide; Kuroda, Shingo; Kimura, Akiko.
Afiliación
  • Nakaigawa N; Department of Urology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan.
  • Tomita Y; Department of Urology, Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-Ku, Niigata, 951-8510, Japan.
  • Tamada S; Department of Urology, Bell Land General Hospital, 500-3 Higashiyama, Naka-Ku, Sakai City, Osaka, 599-8247, Japan.
  • Tatsugami K; Department of Urology, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-Ku, Kitakyushu, 802-8561, Japan.
  • Osawa T; Department of Renal and Genitourinary Surgery, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
  • Oya M; Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
  • Kanayama H; Department of Urology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-Cho, Tokushima, 770-8503, Japan.
  • Miura Y; Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
  • Sassa N; Department of Urology, Aichi Medical University School of Medicine, Yazako-Karimata 1-1, Nagakute, Aichi, 480-1195, Japan.
  • Nishimura K; Department of Urology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
  • Nozawa M; Department of Urology, Kindai University Faculty of Medicine, 377-2 Onohigashi, Osakasayama-Shi, Osaka-Fu, 589-0014, Japan.
  • Masumori N; Department of Urology, Sapporo Medical University School of Medicine, S1 W16, Chuo-Ku, Sapporo, 060-8543, Japan.
  • Miyoshi Y; Department of Urology and Renal Transplantation, Yokohama City University Medical Center, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 326-0004, Japan.
  • Kuroda S; Statistical and Quantitative Sciences, Data Science Institute, Research and Development, Takeda Pharmaceutical Company Limited, 1-1 Doshomachi 4-Chome, Chuo-Ku, Osaka, 540-8645, Japan.
  • Kimura A; Oncology Therapeutic Area Unit for Japan and Asia, Takeda Pharmaceutical Company Limited, 1-1 Doshomachi 4-Chome, Chuo-Ku, Osaka, 540-8645, Japan. akiko.kimura1@takeda.com.
Int J Clin Oncol ; 28(3): 416-426, 2023 Mar.
Article en En | MEDLINE | ID: mdl-36595123
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Inhibidores de Proteínas Quinasas / Neoplasias Renales Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Inhibidores de Proteínas Quinasas / Neoplasias Renales Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Japón